Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Total Valuation
EyePoint Pharmaceuticals has a market cap or net worth of $613.80M. The enterprise value is $79.86M.
Market Cap$613.80M
Enterprise Value$79.86M
Share Statistics
EyePoint Pharmaceuticals has 68,811,740 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,811,740
Owned by Insiders0.87%
Owned by Institutions56.37%
Financial Efficiency
EyePoint Pharmaceuticals’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -39.51%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-39.51%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee262.26K
Profits Per Employee-793.15K
Employee Count165
Asset Turnover0.10
Inventory Turnover1.61
Valuation Ratios
The current PE Ratio of EyePoint Pharmaceuticals is -3.20. EyePoint Pharmaceuticals’s PEG ratio is -0.02.
PE Ratio-3.20
PS Ratio0.00
PB Ratio1.36
Price to Fair Value1.25
Price to FCF-1.94
Price to Operating Cash Flow-2.01
PEG Ratio-0.02
Income Statement
In the last 12 months, EyePoint Pharmaceuticals had revenue of 43.27M and earned -130.87M in profits. Earnings per share was -2.32.
Revenue43.27M
Gross Profit39.56M
Operating Income-145.85M
Pretax Income-130.78M
Net Income-130.87M
EBITDA-129.23M
Earnings Per Share (EPS)-2.32
Cash Flow
In the last 12 months, operating cash flow was -148.18M and capital expenditures -3.13M, giving a free cash flow of -151.31M billion.
Operating Cash Flow-148.18M
Free Cash Flow-151.31M
Free Cash Flow per Share-2.20
Dividends & Yields
EyePoint Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.33
52-Week Price Change9.31%
50-Day Moving Average6.75
200-Day Moving Average7.78
Relative Strength Index (RSI)69.12
Average Volume (3m)818.96K
Important Dates
EyePoint Pharmaceuticals upcoming earnings date is Jul 30, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date―
Financial Position
EyePoint Pharmaceuticals as a current ratio of 7.81, with Debt / Equity ratio of 47.49%
Current Ratio7.81
Quick Ratio7.77
Debt to Market Cap0.00
Net Debt to EBITDA0.60
Interest Coverage Ratio-10.42K
Taxes
In the past 12 months, EyePoint Pharmaceuticals has paid 90.00K in taxes.
Income Tax90.00K
Effective Tax Rate>-0.01
Enterprise Valuation
EyePoint Pharmaceuticals EV to EBITDA ratio is -2.64, with an EV/FCF ratio of -2.62.
EV to Sales7.89
EV to EBITDA-2.64
EV to Free Cash Flow-2.62
EV to Operating Cash Flow-2.71
Balance Sheet
EyePoint Pharmaceuticals has $318.19M in cash and marketable securities with $24.08M in debt, giving a net cash position of -$294.11M billion.
Cash & Marketable Securities$318.19M
Total Debt$24.08M
Net Cash-$294.11M
Net Cash Per Share-$4.27
Tangible Book Value Per Share$5.98
Margins
Gross margin is 79.89%, with operating margin of -337.06%, and net profit margin of -302.43%.
Gross Margin79.89%
Operating Margin-337.06%
Pretax Margin-302.22%
Net Profit Margin-302.43%
EBITDA Margin-298.63%
EBIT Margin-302.19%
Analyst Forecast
The average price target for EyePoint Pharmaceuticals is $25.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.86
Price Target Upside189.91% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast12.04%
EPS Growth Forecast-31.81%